Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models

<p>Supplementary Figure 3: The antitumor effect by FRa expression</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Shigehiro Yagishita (15088446) (author)
Altri autori:	Sho Sato (15352614) (author), Daisuke Shintani (15352611) (author), Tadaaki Nishikawa (15033960) (author), Aiko Ogasawara (22547757) (author), Masanori Yasuda (15352623) (author), Hironori Ishii (22547760) (author), Keiji Furuuchi (20667857) (author), Toshimitsu Uenaka (20667860) (author), Hiroshi Yoshida (15044363) (author), Kosei Hasegawa (15352632) (author), Akinobu Hamada (15352635) (author)
Pubblicazione:	2025
Soggetti:	Cancer Methods and Technology Gynecological Cancers Endometrial cancer Uterine cancer Imaging Imaging probes
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
di: Shigehiro Yagishita (15088446)
Pubblicazione: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
di: Shigehiro Yagishita (15088446)
Pubblicazione: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
di: Shigehiro Yagishita (15088446)
Pubblicazione: (2025)

Supplementary Data1 from Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma
di: Namsoo Kim (21718000)
Pubblicazione: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
di: Arnaud Da Cruz Paula (17316230)
Pubblicazione: (2025)

Data Sheet 1_Low-grade endometrial stromal sarcoma: a case report and literature review.docx
di: Xiaojing Zhao (600854)
Pubblicazione: (2025)

Video 1_Low-grade endometrial stromal sarcoma: a case report and literature review.mp4
di: Xiaojing Zhao (600854)
Pubblicazione: (2025)

Data Sheet 1_Multiparametric MRI-based radiomics and deep learning for differentiating uterine serous carcinoma from endometrioid carcinoma: a multicenter retrospective study.docx
di: Yi Shen (152956)
Pubblicazione: (2025)

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
di: Ryan D. Chow (15109654)
Pubblicazione: (2025)

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
di: Ryan D. Chow (15109654)
Pubblicazione: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
di: Ryan D. Chow (15109654)
Pubblicazione: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
di: Ryan D. Chow (15109654)
Pubblicazione: (2025)

Figure_S1 from Impact of Changes in Obesity and Abdominal Obesity on Endometrial Cancer Risk in Young Korean Women: A Nationwide Cohort Study
di: Jung Heo (22364700)
Pubblicazione: (2025)

Supplementary Figure S1 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Supplementary Figure S2 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Supplementary Figure S3 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Supplementary Figure S4 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Supplementary Figure S5 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Supplementary Figure S6 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
di: Britt K. Erickson (15028112)
Pubblicazione: (2025)

Figure S1 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S2 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S3 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S4 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S5 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S6 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S7 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure S8 from <i>UBE2C</i>-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression
di: Rong Zhao (15212734)
Pubblicazione: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
di: Niccolò G. Santin (22229756)
Pubblicazione: (2025)

Table S1 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
di: Isabelle Gregga (16673534)
Pubblicazione: (2025)

Table S2 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
di: Isabelle Gregga (16673534)
Pubblicazione: (2025)

Table S3 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
di: Isabelle Gregga (16673534)
Pubblicazione: (2025)

Table S4 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
di: Isabelle Gregga (16673534)
Pubblicazione: (2025)

Table S5 from Predicted Proteome Association Studies of Breast, Prostate, Ovarian, and Endometrial Cancers Implicate Plasma Protein Regulation in Cancer Susceptibility
di: Isabelle Gregga (16673534)
Pubblicazione: (2025)